CRISPR Therapeutics AG
CRSP
$54.13
-$0.19-0.35%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 1.72B | 1.86B | 1.90B | 1.94B | 2.00B |
Total Receivables | -- | -- | 27.10M | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 8.93M | 8.83M | 6.21M | 8.25M | 8.79M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 3.50M | 3.50M | -- | -- | -- |
Total Current Assets | 1.73B | 1.87B | 1.94B | 1.94B | 2.01B |
|
|||||
Total Current Assets | 1.73B | 1.87B | 1.94B | 1.94B | 2.01B |
Net Property, Plant & Equipment | 262.57M | 269.70M | 277.55M | 284.83M | 291.57M |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 10.88M | 28.79M | 27.35M | 27.41M | 26.66M |
Total Assets | 2.03B | 2.17B | 2.24B | 2.26B | 2.34B |
|
|||||
Total Accounts Payable | 9.75M | 13.06M | 14.71M | 15.58M | 9.45M |
Total Accrued Expenses | 27.37M | 28.29M | 39.41M | 35.55M | 39.05M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 18.03M | 17.51M | 17.29M | 16.88M | 16.45M |
Total Finance Division Other Current Liabilities | 49.21M | 60.59M | 16.38M | 21.80M | 62.87M |
Total Other Current Liabilities | 49.21M | 60.59M | 16.38M | 21.80M | 62.87M |
Total Current Liabilities | 104.36M | 119.45M | 87.78M | 89.81M | 127.82M |
|
|||||
Total Current Liabilities | 104.36M | 119.45M | 87.78M | 89.81M | 127.82M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 197.43M | 201.85M | 206.41M | 210.66M | 214.85M |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 16.80M | 15.64M | 15.77M | 16.00M | 16.23M |
Total Liabilities | 318.59M | 336.94M | 309.95M | 316.47M | 358.90M |
|
|||||
Common Stock & APIC | 3.42B | 3.33B | 3.30B | 3.26B | 3.23B |
Retained Earnings | -1.71B | -1.50B | -1.37B | -1.33B | -1.24B |
Treasury Stock & Other | 3.98M | 4.07M | 1.78M | 10.50M | -2.94M |
Total Common Equity | 1.71B | 1.83B | 1.93B | 1.94B | 1.98B |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 1.71B | 1.83B | 1.93B | 1.94B | 1.98B |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 1.71B | 1.83B | 1.93B | 1.94B | 1.98B |
|